Novelion Therapeutics Inc. (NVLN) Analysts See $-1.58 EPS

March 20, 2018 - By Peter Erickson

 Novelion Therapeutics Inc. (NVLN) Analysts See $ 1.58 EPS

Analysts expect Novelion Therapeutics Inc. (NASDAQ:NVLN) to report $-1.58 EPS on March, 21.They anticipate $0.18 EPS change or 10.23 % from last quarter’s $-1.76 EPS. After having $-0.89 EPS previously, Novelion Therapeutics Inc.’s analysts see 77.53 % EPS growth. The stock decreased 5.07% or $0.23 during the last trading session, reaching $4.31. About 33,370 shares traded. Novelion Therapeutics Inc. (NASDAQ:NVLN) has risen 31.51% since March 20, 2017 and is uptrending. It has outperformed by 14.81% the S&P500.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. The company has market cap of $80.61 million. The Company’s product portfolio includes MYALEPT , a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. It currently has negative earnings. The company's orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.